In routine setting, interdisciplinary teams satisfactorily manage extravasations
the ONA take:
In a routine setting, the standardized management of cytotoxic extravasations of antitumoral compounds by an interdisciplinary task force resulted in a satisfactory outcome, a study published in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to assess extravasations of antitumoral compounds and the efficacy of its structured interdisciplinary managements in a routine setting. Researchers longitudinally observed 169 patients who were managed for cytotoxic extravasation according to a prospective approach. Patients underwent surgery if conservative measures failed.
Results showed that conservative management was successful in 91.7% of patients. Researchers found that extravasations of anthracyclines (i.e., doxorubicin), platinum compounds (i.e., cisplatin), vinca alkaloids (i.e., vincristine), and taxanes (i.e., paclitaxel) were associated with erythema, edema, and pain.
The median duration until full resolution of symptoms was 55 days for anthracyclines, 27 days for taxanes and vinca alkaloids, and 14 days for platinum compounds, with statistical significance between the vesicants.
The findings suggest that "the proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment."
In a routine setting, the standardized management of cytotoxic extravasations resulted in a satisfactory outcome.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|